

DEAV2002/0050 US NP

R5 is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

A is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R7 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R8 is -(C=O)-X;

X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

m is 1 or 2; and

n is 1 or 2;

and pharmaceutically acceptable salts thereof.